IP Library › Granted Patent US 12,447,127
Granted Patent B2
US 12,447,127 · App. 17/732,224 · Granted Oct 21, 2025

Thermostable vaccine compositions and methods of preparing the same

Inventors: Kimberly Hassett (Medford, MA); Pradyot Nandi (Denver, CO); John Carpenter (Littleton, CO); Theodore Randolph (Niwot, CO)
Assignee: The Regents of the University of Colorado, a body corporate
A61K9/19A61K39/00A61K39/39A61K47/26A61K2039/55505A61K2039/55572Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,127
App. No.
17/732,224
Granted
Oct 21, 2025
Kind
B2
Abstract

The present invention relates generally to the field of immunogenic compositions containing volatile salts. In certain embodiments, compositions and methods disclosed herein relate to producing and using novel combinations to create frozen immunogenic agents bound to adjuvant having improved formulations and improved consistency of distribution of adjuvant for storage and subsequent delivery to a subject in need thereof.

Claims (22)

1. A method of preparing an immunologically-active adjuvant-bound immunogenic composition, the method comprising:

(a) providing an aluminum-salt adjuvant; a buffering agent wherein the buffering agent further comprises a volatile salt, the volatile salt is selected from the group consisting of ammonium acetate, ammonium formate, ammonium carbonate, ammonium bicarbonate, triethylammonium acetate, triethylammonium formate, triethylammonium carbonate, trimethylamine acetate trimethylamine formate, trimethylamine carbonate, pyridinal acetate and pyridinal formate; a glass-forming agent wherein the glass-forming agent is selected from the group consisting of trehalose, sucrose, ficoll, dextran, maltotriose, lactose, mannitol and glycine, hydroxyethyl starch, glycine, cyclodextrin and povidone; and at least one protein antigen;

(b) combining (a) together to create a liquid immunogenic formulation; and

(c) freezing the liquid immunogenic formulation in (b) to create a frozen immunogenic formulation.

2. The method according to claim 1 , further comprising, (d) lyophilizing the frozen immunogenic formulation in (c) to create an essentially dried immunogenic composition.

3. The method according to claim 2 , reconstituting the essentially dried immunogenic composition in a pharmaceutically acceptable excipient.

4. The method according to claim 1 , the immunologically-active adjuvant-bound immunogenic composition further comprising an additional buffering agent, wherein the additional buffering agent is selected from the group consisting of acetate, succinate, citrate, prolamine, arginine, glycine, histidine, borate, carbonate, and phosphate.

5. The method according to claim 1 , wherein the at least one protein antigen is selected from or derived from the group consisting of rotavirus, foot and mouth disease virus, influenza A virus, influenza B virus, influenza C virus, H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H1N7, human parainfluenza type 2, herpes simplex virus, Epstein-Barr virus, varicella virus, porcine herpesvirus 1, cytomegalovirus, lyssavirus, Bacillus anthracis , anthrax PA and derivatives, poliovirus, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis E, distemper virus, Venezuelan equine encephalomyelitis, feline leukemia virus, reovirus, respiratory syncytial virus, Lassa fever virus, polyoma tumor virus, canine parvovirus, papilloma virus, tick borne encephalitis virus, rinderpest virus, human rhinovirus species, Enterovirus species, Mengovirus, paramyxovirus, avian infectious bronchitis virus, human T-cell leukemia-lymphoma virus 1, human immunodeficiency virus-1, human immunodeficiency virus-2, lymphocytic choriomeningitis virus, parvovirus B19, adenovirus, rubella virus, yellow fever virus, dengue virus, bovine respiratory syncytial virus, corona virus, Bordetella pertussis, Bordetella bronchiseptica, Bordetella parapertussis, Brucella abortis, Brucella melitensis, Brucella suis, Brucella ovis, Brucella species, Escherichia coli, Salmonella species, Salmonella typhi , Streptococci, Vibrio cholera, Vibrio parahaemolyticus, Shigella, Pseudomonas, tuberculosis, avium , Bacille Calmette Guerin, Mycobacterium leprae , Pneumococci, Staphylococci, Enterobacter species, Rochalimaia henselae, Pasteurella haemolytica, Pasteurella multocida, Chlamydia trachomatis, Chlamydia psittaci, Lymphogranuloma venereum, Treponema pallidum, Haemophilus species, Mycoplasma bovigenitalium, Mycoplasma pulmonis, Mycoplasma species, Borrelia burgdorferi, Legionella pneumophila, Clostridium botulinum, Corynebacterium diphtheriae, Yersinia entercolitica, Rickettsia rickettsii, Rickettsia typhi, Rickettsia prowazekii, Ehrlichia chaffeensis, Anaplasma phagocytophilum, Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae , Schistosomes, trypanosomes, Leishmania species, Filarial nematodes , trichomoniasis, sarcosporidiasis, Taenia saginata, Taenia solium, Leishmania, Toxoplasma gondii, Trichinella spiralis , coccidiosis, Eimeria tenella, Cryptococcus neoformans, Candida albican, Aspergillus fumigatus , coccidioidomycosis, Neisseria gonorrhoeae , malaria circumsporozoite protein, malaria merozoite protein, trypanosome surface antigen protein, pertussis, alphaviruses, adenovirus, diphtheria toxoid, tetanus toxoid, meningococcal outer membrane protein, streptococcal M protein, Influenza hemagglutinin, cancer antigen, tumor antigens, toxins, Clostridium perfringens epsilon toxin, ricin toxin, pseudomonas exotoxin, exotoxins, neurotoxins, cytokines, cytokine receptors, monokines, monokine receptors, plant pollens, animal dander, and dust mites.

6. The method according to claim 1 , wherein the glass-forming agent comprises trehalose and the trehalose is present in a weight-to-volume concentration of about 5% to about 20% in the liquid immunogenic formulation in (b).

7. The method according to claim 1 , wherein freezing the liquid immunogenic formulation in (b) to create a frozen immunogenic formulation comprises freezing by tray freezing, shelf freezing, spray-freezing, or shell-freezing.

8. The method according to claim 1 , wherein the liquid immunogenic composition in (b) is prepared as a hypertonic mixture prior to freezing.

9. The method according to claim 8 , further comprising, (d) lyophilizing the frozen immunogenic formulation in (c) to create an essentially dried immunogenic composition; and reconstituting the essentially dried immunogenic composition to an isotonic aqueous formulation.

10. The method of claim 3 , further comprising, administering the reconstituted essentially dried immunogenic composition to a subject.

11. The method according to claim 10 , wherein the aluminum-salt adjuvant of the immunogenic composition is selected from the group consisting of aluminum hydroxide, aluminum phosphate and aluminum sulfate.

12. The method according to claim 10 , wherein the aluminum-salt adjuvant of the immunogenic composition is aluminum hydroxide.

13. The method according to claim 10 , wherein anions of the buffering agent of the immunogenic composition are selected from the group consisting of acetate, succinate, citrate, prolamine, arginine, glycine, histidine, borate, carbonate, and phosphate.

14. The method according to claim 10 , wherein the volatile salt of the immunogenic composition is ammonium acetate or ammonium formate.

15. The method according to claim 10 , wherein the glass-forming agent of the immunogenic composition is selected from the group consisting of trehalose, sucrose, and hydroxyethyl starch.

16. The method according to claim 10 , wherein the at least one protein antigen of the immunogenic composition is selected from or derived from the group consisting of rotavirus, foot and mouth disease virus, influenza A virus, influenza B virus, influenza C virus, H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H1N7, human parainfluenza type 2, herpes simplex virus, Epstein-Barr virus, varicella virus, porcine herpesvirus 1, cytomegalovirus, lyssavirus, Bacillus anthracis , anthrax PA and derivatives, poliovirus, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis E, distemper virus, Venezuelan equine encephalomyelitis, feline leukemia virus, reovirus, respiratory syncytial virus, Lassa fever virus, polyoma tumor virus, canine parvovirus, papilloma virus, tick borne encephalitis virus, rinderpest virus, human rhinovirus species, Enterovirus species, Mengovirus, paramyxovirus, avian infectious bronchitis virus, human T-cell leukemia-lymphoma virus 1, human immunodeficiency virus-1, human immunodeficiency virus-2, lymphocytic choriomeningitis virus, parvovirus B19, adenovirus, rubella virus, yellow fever virus, dengue virus, bovine respiratory syncytial virus, corona virus, Bordetella pertussis, Bordetella bronchiseptica, Bordetella parapertussis, Brucella abortis, Brucella melitensis, Brucella suis, Brucella ovis, Brucella species, Escherichia coli, Salmonella species, Salmonella typhi , Streptococci, Vibrio cholera, Vibrio parahaemolyticus, Shigella, Pseudomonas, tuberculosis, avium , Bacille Calmette Guerin, Mycobacterium leprae , Pneumococci, Staphylococci Enterobacter species, Rochalimaia henselae, Pasteurella haemolytica, Pasteurella multocida, Chlamydia trachomatis, Chlamydia psittaci, Lymphogranuloma venereum, Treponema pallidum, Haemophilus species, Mycoplasma bovigenitalium, Mycoplasma pulmonis, Mycoplasma species, Borrelia burgdorferi, Legionella pneumophila, Clostridium botulinum, Corynebacterium diphtheriae, Yersinia entercolitica, Rickettsia rickettsii, Rickettsia typhi, Rickettsia prowazekii, Ehrlichia chaffeensis, Anaplasma phagocytophilum, Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae , Schistosomes, trypanosomes, Leishmania species, Filarial nematodes , trichomoniasis, sarcosporidiasis, Taenia saginata, Taenia solium, Leishmania, Toxoplasma gondii, Trichinella spiralis , coccidiosis, Eimeria tenella, Cryptococcus neoformans, Candida albican, Aspergillus fumigatus , coccidioidomycosis, Neisseria gonorrhoeae , malaria circumsporozoite protein, malaria merozoite protein, trypanosome surface antigen protein, pertussis, alphaviruses, adenovirus, diphtheria toxoid, tetanus toxoid, meningococcal outer membrane protein, streptococcal M protein, Influenza hemagglutinin, cancer antigen, tumor antigens, toxins, Clostridium perfringens epsilon toxin, ricin toxin, pseudomonas exotoxin, exotoxins, neurotoxins, cytokines, cytokine receptors, monokines, monokine receptors, plant pollens, animal dander, and dust mites.

17. The method according to claim 10 , wherein the protein antigen comprises a protein agent derived from a virus.

18. The method according to claim 10 , wherein administering the reconstituted immunogenic composition to a subject comprises administering the reconstituted immunogenic composition to the subject for reducing onset of a condition caused by the at least one protein antigen or the organism from which the at least one protein antigen is derived.

19. The method according to claim 10 , wherein administering the reconstituted immunogenic composition to the subject induces an immune response in the subject comprising at least one of humoral immunity and cell-mediated immunity to the at least one protein antigen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: HASSETT, KIMBERLY; NANDI, PRADYOT; CARPENTER, JOHN; RANDOLPH, THEODORE
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 059817/0279 →
Continuity (5)
Continuation 16448647 · Jun 21, 2019
Continuation 15694023 · Sep 1, 2017
Continuation 13474661 · May 17, 2012
Provisional Application 61487206 · May 17, 2011
Related Publication 20230007972A1 · Jan 12, 2023
References Cited (86)
US 5855894A · Brown et al. · 1999 [cited by applicant]
US 5902565A · Cox et al. · 1999 [cited by applicant]
US 5919665A · Williams · 1999 [cited by applicant]
US 6391315B1 · Takahashi et al. · 2002 [cited by applicant]
US 6592872B1 · Klimpel et al. · 2003 [cited by applicant]
US 6623762B2 · Roser et al. · 2003 [cited by applicant]
US 6890512B2 · Roser et al. · 2005 [cited by applicant]
US 7037510B2 · Andersen et al. · 2006 [cited by applicant]
US 7097965B2 · Klimpel et al. · 2006 [cited by applicant]
US 8444991B2 · Randolph et al. · 2013 [cited by applicant]
US 8512679B2 · Hyde et al. · 2013 [cited by applicant]
US 8808710B2 · Randolph et al. · 2014 [cited by applicant]
US 9731020B2 · Harel et al. · 2017 [cited by applicant]
US 9744227B2 · Bronshtein · 2017 [cited by applicant]
US 10532093B2 · Gill et al. · 2020 [cited by applicant]
US 11491111B2 · Hassett et al. · 2022 [cited by applicant]
US 20030202978A1 · Maa et al. · 2003 [cited by applicant]
US 20050186254A1 · Roser et al. · 2005 [cited by applicant]
US 20090304799A1 · Baker, Jr. et al. · 2009 [cited by applicant]
US 20100158951A1 · Randolph et al. · 2010 [cited by applicant]
EP 0156242B1 · 1985 [cited by applicant]
WO 9415636A1 · 1994 [cited by applicant]
WO 9533488A1 · 1995 [cited by applicant]
WO 9813065A1 · 1998 [cited by applicant]
WO 2000053215A2 · 2000 [cited by applicant]
WO 0193829A2 · 2001 [cited by applicant]
WO 2008118691A2 · 2008 [cited by applicant]
Clausi, A. L. et al., “Inhibition of Aggregation of Aluminum Hydroxide Adjuvant during Freezing and Drying,” Journal of Pharmaceutical Sciences vol. 97, No. 6, Jul. 3, 2007, pp. 2049-2061. [cited by applicant]
Hassett, K. J., et al., “Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization,” European Journal of Pharmaceutics and Biopharmaceutics 85, 2013, pp. 279-286. [cited by applicant]
Wolff, L. et al., “Protection of aluminum hydroxide during lyophilisation as an adjuvant fro freeze-dried vaccines,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2008, pp. 116-126. [cited by applicant]
Clarkson, J. et al., “Protein Denaturation in Foam,” J Colloid Interface Science, Jul. 15, 1999, pp. 323-332. [cited by applicant]
Jangle, R. D., et al., “Vacuum Foam Drying: An Alternative to Lyophilization for Biomolecule Preservation,” Indian Journal of Pharmaceutical Sciences, Mar. 6, 2012, pp. 91-100. [cited by applicant]
Clapp, T. et al., “Vaccines with Aluminum-Containing Adjuvants: Optimizing Vaccine Efficacy and Thermal Stability,” J Pharma. Sci. 100, Feb. 2011, pp. 388-401. [cited by applicant]
Woodward et al. (2003) Infect. Immun. 71(5):2941-2944 “Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice”. [cited by applicant]
Zapata et al. (1984) J Pharm Sci 73(1):3-8 “Mechanism of freeze·thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels”. [cited by applicant]
Maa et al., “Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization,” (2003) Pharmaceutical Research 20(7):969-977. [cited by applicant]
Landau, S. I. {Ed.). (1986). International Dictionary of Medicine and Biology, vol. II. John Wiley & Sons New York, NY. p. 1659. [cited by applicant]
Arnon (1986) J. Infect. Dis. 154:201-206 “Infant Botulism: Anticipating the Second Decade”. [cited by applicant]
Burrell et al. (1999) Vaccine I 7(20-21):2599-2603 “Stability of aluminium-containing adjuvants to autoclaving”. [cited by applicant]
Callahan et al. (1991) Pharm. Res. 8(7):851-858 “The importance of surface charge in the optimization of antigen- adjuvant interactions”. [cited by applicant]
Cato et al. (1986) Bergey's Manual® of Systematic Bacteriology, Sneath et al. editors, vol. 2, pp. 1141-1200, Williams & Wilkins “Clostridium”. [cited by applicant]
Caya (2001) Surv Ophthalmol 46( 1 ): 25-34 “Clostridium botulinum and the ophthalmologist: a review of botulism, including biological warfare ramifications ofbotulinum toxin”. [cited by applicant]
Chang et al. (1997) PDA J Pharm Sci Technol 51(1):25-29 “Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant”. [cited by applicant]
Chang et al. (2001) Vaccine 19(20-22):2884-2889 “Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits”. [cited by applicant]
Cox and Coulter (1997) Vaccine 15(3):248-256 “Adjuvants—a classification and review of their modes of action”. [cited by applicant]
DePaz et al. (2005) Vaccine 23: 4029-4035 “Formulation of Botulinum Neurotoxin Heavy Chain Fragments for Vaccine Deve••opment: Mechanisms of Adsorption to an Aluminum-Containing Adjuvant”. [cited by applicant]
Diminsky et al. (1999) Vaccine 18(1-2):3-17 “Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles”. [cited by applicant]
Estey et al. (2009) Journal of Pharmaceutical Sciences 98(9):2994-3012 “Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by lysc peptide map•ping and MALDI-TOF m… [cited by applicant]
Eubanks et al. (2007) Proc. Nat. Acad. Sci. 104(8):2602-2607 “An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists”. [cited by applicant]
Franz et al. (1993) in Botulinum and Tetanus Neurotoxins, B. R. DasGupta, ed., Plenum Press, New York pp. 473-476 “Efficacy of Prophylactic and Therapeutic Administration of Antitoxin for Inh••lation Botulism”. [cited by applicant]
Gill (1982) Microbiol Rev 46(1):86-94 “Bacterial toxins: a table of lethal amounts”. [cited by applicant]
Goldberg S, Davis JA, Hem JD. 1996. In Sposito G, editor The Environmental Chemistry of Aluminum, 2nd ed., Boca Raton, FL: Lewis Publishers. pp. 271-331 “The Surface Chemistry of Aluminum Oxides and Hydroxides”. [cited by applicant]
Grun and Maurer (1989) Cell Immunol 121(1):134-145 “Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses”. [cited by applicant]
Gupta and Rost (2000) Vaccine Adjuvants: Preparation Methods and Research Protocols, ed., Totowa, NJ: Humana Press Inc., O'Hagan D, editor, pp. 65-89 “Aluminum Compounds as Vaccine Adjuvants”. [cited by applicant]
Gupta and Siber (1995) Vaccine 13(14):1263-1276 “Adjuvants for Human Vaccines—Current Status, Problems and Future-Prospects”. [cited by applicant]
Gupta et al. (1992) Pharmaceutical Biotechnology 6:229-248 “Adju vant Properties of Aluminum and Calcium Compounds”. [cited by applicant]
Hatheway (1990) Clin. Microbiol. Rev. 3:66-98 “Toxigenic Clostridia”. [cited by applicant]
Hatley and Blair (1999) J. Molecular Catalysis B: Enzymatic 7: 11-19 “Stabilisation and delivery of labile materials by amorphous carb••hydrates and their derivatives”. [cited by applicant]
He et al. (2002) Clinical and Diagnos. Lab. Immunol. 9(5): 1021-1224 “Calcium Phosphate Nanoparticles Induce Mucosa! Immunity and Protection against Herpes Simplex Virus Type 2”. [cited by applicant]
Hem and White (1984) J Parenter Sci Technol 38(1):2-10 “Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines”. [cited by applicant]
Lyer et al. (2003) Vaccine 21(11-12):1219-1223 “Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production”. [cited by applicant]
Johnston et al. (2002) J Pharm Sci 91(7): 1702-1706 “Measuring the surface area of aluminum hydroxide adjuvant”. [cited by applicant]
Jones et al. (2005) J Biol Chem 280(14):13406-13414 “Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens”. [cited by applicant]
Lindblad (2004) Immunol. Cell. Biol. 82(5):497-505 “Aluminium compounds for use in vaccines”. [cited by applicant]
Maa et al. (2003) J Pharm Sci 92(2):319-332 “Stabilization of alum•adjuvanted vaccine dry powder formulations: mechanism and appl••cation”. [cited by applicant]
Maa et al. (2004) J. Pharm. Sci. 93(7): 1912-1923 “Influenza Vaccine Powder Formulation Development : Spray- Freeze-Drying and Sta•bility Evaluation”. [cited by applicant]
Macdonald et al. (1986) Am. J. Epidemiol. 124:79 “The Changing Epidemiology of Adult Botulism in the United States”. [cited by applicant]
Mahon (2001) Curr. Med. Chem. 8(9):1057-1075 “The rational design of vaccine adjuvants for mucosal and neonatal immunization”. [cited by applicant]
Morefield et al. (2005) Vaccine 23(13):1588-1595 “Role of alumi.num-containing adjuvants in antigen internalization by dendritic cells in vitro”. [cited by applicant]
Nygaard et al. (2004) Toxicol Sci 82(2):515-524 “The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass”. [cited by applicant]
Oguma, et al. ( 1995) Micro biol Immunol 39(3): 161-8 “Structure and function of Clostridium botulinum toxins”. [cited by applicant]
O'Hagan et al. (2001) Biomol Eng 18(3):69-85 “Recent developments in adjuvants for vaccines against infectious diseases”. [cited by applicant]
Remington's Pharmaceutical Sciences ( 1990) 18th Ed. Gennaro Ed., Mack Publishing Co., Easton, Pennsylvania pp. 241-243. [cited by applicant]
Rinella et al. (1996) Vaccine, 14(4):298-300 “Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins”. [cited by applicant]
Roy et al. (2005) JPharm Sci 94(2):382-96 “Effects ofbenzyl alcohol on aggregation of recombinant human interleukin-I-receptor antagonist in reconstituted lyophilized formulations”. [cited by applicant]
Singh and O'Hagan (1999) Nat Biotechnol 17(11):1075-81 “Advances in vaccine adjuvants”. [cited by applicant]
Sinha et al. (2007) J Biotechnol 127(3):462-474 “Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBONTE(H(c )): … [cited by applicant]
Smith (1998) Toxicon 36(11):1539-48 “Development of recombinant vaccines for botulinum neurotoxin”. [cited by applicant]
Smith et al. (2004) Mov Disord 19 Suppl 8:S48-52 “Roads from vaccines to therapies”. [cited by applicant]
Smith et al. (2005) Infection Immun.73(9):5450-5457 “Sequence variation within Botulinum Neurotoxin Serotypes impacts antibody binding and neutralization”. [cited by applicant]
Sugiyama (1980) Microbiol. Rev. 44:419-448 “Clostridium botulinum neurotoxin”. [cited by applicant]
Swartz, M. N., “Anaerobic Spore-Forming Bacilli: the Clostridia,” pp. 633-646. [cited by applicant]
Shalaev et al., “Thermophysical properties of pharmaceutically com•patible buffers at sub-zero temperatures: Implications for freeze.drying,” (2002) 19(2):195-201. [cited by applicant]
Thai et al. (2004) J. Biol. Chem. 279(48):50257-50266 “Antigen stability controls antigen presentation”. [cited by applicant]
Vessely et al. (2007) J. Pharmaceut. Sci., 96(9):2375-2389 “Effects of Solution Conditions and Surface Chemistry on the Adsorption of Three Recombinant Botulinum Neurotoxin Antigens to Aluminum Salt Adjuvants”. [cited by applicant]
White and Hem (2000) Dev Biol (Basel) 103:217-28 “Characterization of aluminium-containing adjuvants”. [cited by applicant]